Passive Antibody-Mediated Immunotherapy for the Treatment of Malignant Gliomas

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 67-76

  Mitra, Siddhartha ^a   Li, Gordon ^a   Harsh IV, Griffith R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Epidermal growth factor receptor; Epidermal growth factor receptor variant III; Glioblastoma multiforme; Monoclonal antibody; Tenascin C

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425; MONOCLONAL ANTIBODY 806; MONOCLONAL ANTIBODY 81C6; MONOCLONAL ANTIBODY 81C6 I 131; MONOCLONAL ANTIBODY Y10; NIMOTUZUMAB; SCLEROPROTEIN; TEMOZOLOMIDE; TENASCIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER SURVIVAL; CELL EXPANSION; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; LUNG CANCER; MELANOMA; NEUROSURGERY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; SURVIVAL TIME; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; EXTRACELLULAR MATRIX PROTEINS; GLIOMA; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70450207586     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.08.010     Document Type: Review

References (91)

1. Furnari F.B., Fenton T., Bachoo R.M., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21 (2007) 2683-2710
2. Lefranc F., Brotchi J., and Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23 (2005) 2411-2422
3. Bolesta E., Kowalczyk A., Wierzbicki A., et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res 65 (2005) 3410-3418
4. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 23 (2005) 1147-1157
5. Farah R.A., Clinchy B., Herrera L., et al. The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Expr 8 (1998) 321-356
6. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
7. Diaz Miqueli A., Rolff J., Lemm M., et al. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 100 (2009) 950-958
8. Leonard D.S., Hill A.D., Kelly L., et al. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 89 (2002) 262-271
9. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
10. van Dijk M.A., and van de Winkel J.G. Human antibodies as next generation therapeutics. Curr Opin Chem Biol 5 (2001) 368-374
11. Yang X.D., Jia X.C., Corvalan J.R., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 (2001) 17-23
12. Nadler L.M., Stashenko P., Hardy R., et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40 (1980) 3147-3154
13. Cragg M.S., French R.R., and Glennie M.J. Signaling antibodies in cancer therapy. Curr Opin Immunol 11 (1999) 541-547
14. Glennie M.J. Signaling antibodies for the treatment of neoplastic disease. Dis markers 16 (2000) 63
15. Eisenthal A., Cameron R.B., and Rosenberg S.A. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 144 (1990) 4463-4471
16. Eisenthal A., and McIntosh J.K. Effect of recombinant human tumor necrosis factor alpha on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules. Cancer Immunol Immunother 31 (1990) 243-249
17. Shiloni E., Eisenthal A., Sachs D., et al. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 138 (1987) 1992-1998
18. Bleeker W.K., Lammerts van Bueren J.J., van Ojik H.H., et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173 (2004) 4699-4707
19. Baselga J., and Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 64 (1994) 127-154
20. Goldstein N.I., Prewett M., Zuklys K., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (1995) 1311-1318
21. Gutowski M.C., Briggs S.L., and Johnson D.A. Epidermal growth factor receptor-reactive monoclonal antibodies: xenograft antitumor activity alone and as drug immunoconjugates. Cancer Res 51 (1991) 5471-5475
22. Masui H., Kawamoto T., Sato J.D., et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44 (1984) 1002-1007
23. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3 (1997) 2703-2707
24. Mendelsohn J., and Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 33 (2006) 369-385
25. Modjtahedi H., Eccles S., Box G., et al. Immunotherapy of human tumor xenografts over expressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67 (1993) 254-261
26. Modjtahedi H., Eccles S.A., Box G., et al. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell Biophys 22 (1993) 129-146
27. Wikstrand C.J., Cokgor I., Sampson J.H., et al. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev 18 (1999) 451-464
28. Prins R.M., and Liau L.M. Cellular immunity and immunotherapy of brain tumors. Front Biosci 9 (2004) 3124-3136
29. Wykosky J., Gibo D.M., Stanton C., et al. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3 (2005) 541-551
30. Bigner S.H., Burger P.C., Wong A.J., et al. Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol 47 (1988) 191-205
31. Bigner S.H., Humphrey P.A., Wong A.J., et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50 (1990) 8017-8022
32. Garcia de Palazzo I.E., Adams G.P., Sundareshan P., et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53 (1993) 3217-3220
33. Humphrey P.A., Gangarosa L.M., Wong A.J., et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun 178 (1991) 1413-1420
34. Humphrey P.A., Wong A.J., Vogelstein B., et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48 (1988) 2231-2238
35. Ekstrand A.J., James C.D., Cavenee W.K., et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51 (1991) 2164-2172
36. Harding J., and Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 41 (2005) 107-127
37. Ferguson K.M. Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans 32 (2004) 742-745
38. Eller J.L., Longo S.L., Hicklin D.J., et al. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 51 (2002) 1005-1013 [discussion: 1013-4]
39. Eller J.L., Longo S.L., Kyle M.M., et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 56 (2005) 155-162 [discussion: 162]
40. Combs S.E., Schulz-Ertner D., Hartmann C., et al. Phase I/II study of cetuximab plus temozolomide as radiochemotherapy for primary glioblastoma (GERT). J Clin Oncol 26 (2008) May 20 Suppl; abstr 2077
41. Neyns B., Sadones J., Joosens E., et al. A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. J Clin Oncol 26 (2008) May 20 Suppl; abstr 2017
42. Hasselbalch B, Lassen U, Soerensen M, et al. A phase 2 trial with cetuximab, bevacizumab and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolomide. Neuro-oncology 10 Abstract: Society of Neuro-Oncology Annual Meeting 2008. Las Vegas, Nevada, November 21-23, 2008.
43. Casaco A., Lopez G., Garcia I., et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 7 (2008) 333-339
44. Bender H., Takahashi H., Adachi K., et al. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 52 (1992) 121-126
45. Quang T.S., and Brady L.W. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58 (2004) 972-975
46. Humphrey P.A., Wong A.J., Vogelstein B., et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 87 (1990) 4207-4211
47. Wong A.J., Ruppert J.M., Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89 (1992) 2965-2969
48. Johns T.G., Stockert E., Ritter G., et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98 (2002) 398-408
49. Jungbluth A.A., Stockert E., Huang H.J., et al. A monoclonal antibody recognizing human cancers with amplification/over expression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 100 (2003) 639-644
50. Perera R.M., Narita Y., Furnari F.B., et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11 (2005) 6390-6399
51. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97 (2000) 7503-7508
52. Mitchell D.A., Fecci P.E., and Sampson J.H. Immunotherapy of malignant brain tumors. Immunol Rev 222 (2008) 70-100
53. Reist C.J., Archer G.E., Kurpad S.N., et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55 (1995) 4375-4382
54. Reist C.J., Archer G.E., Wikstrand C.J., et al. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 57 (1997) 1510-1515
55. Reist C.J., Batra S.K., Pegram C.N., et al. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl Med Biol 24 (1997) 639-647
56. Kuan C.T., Reist C.J., Foulon C.F., et al. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin Cancer Res 5 (1999) 1539-1549
57. Li G., and Wong A. EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines 7 (2008) 977-985
58. Birlik B.C.S., and Ozer E. Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas. Neuropathol Appl Neurobiol 32 (2006) 532-538
59. Leon S., Folkerth R., and Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77 (1996)
60. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 (2007) 1253-1259
61. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722-4729
62. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
63. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4 Suppl 2 (2004) S62-S68
64. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
65. de Groot J.F., and Yung W.K. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 14 (2008) 279-285
66. Wagner S.A., Desjardins A., Reardon D.A., et al. Vredenburgh update on survival from the original phase 2 trial of bevacizumab and irinotecan in recurrent malignant gliomas. J Clin Oncol 26 (2008) May 20 Suppl: abst 2021
67. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70 (2008) 779-787
68. Fine H.A. Promising new therapies for malignant gliomas. Cancer J 13 (2007) 349-354
69. Behrem S., Zarkovic K., Eskinja N., et al. Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation. Pathol Oncol Res 11 (2005) 229-235
70. Jallo G.I., Friedlander D.R., Kelly P.J., et al. Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis. Neurosurgery 41 (1997) 1052-1059
71. Leins A., Riva P., Lindstedt R., et al. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98 (2003) 2430-2439
72. Sarkar S., Nuttall R.K., Liu S., et al. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 66 (2006) 11771-11780
73. Brack S.S., Silacci M., Birchler M., et al. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12 (2006) 3200-3208
74. He X., Archer G.E., Wikstrand C.J., et al. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J Neuroimmunol 52 (1994) 127-137
75. Silacci M., Brack S.S., Spath N., et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 19 (2006) 471-478
76. Reardon D.A., Zalutsky M.R., and Bigner D.D. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther 7 (2007) 675-687
77. Reardon D.A., Akabani G., Coleman R.E., et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20 (2002) 1389-1397
78. Reardon D.A., Akabani G., Coleman R.E., et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24 (2006) 115-122
79. Reardon D.A., Quinn J.A., Akabani G., et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 47 (2006) 912-918
80. Omidfar K., Rasaee M.J., Kashanian S., et al. Studies of thermostability in Camelus bactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pichia. Biotechnol Appl Biochem 46 (2007) 41-49
81. Omidfar K., Rasaee M.J., Modjtahedi H., et al. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus. Tumour Biol 25 (2004) 179-187
82. Omidfar K., Rasaee M.J., Modjtahedi H., et al. Production of a novel camel single-domain antibody specific for the type III mutant EGFR. Tumour Biol 25 (2004) 296-305
83. Adams G.P., and Weiner L.M. Intracellular single-chain Fv antibodies-a knockout punch for neoplastic cells?. Gynecol Oncol 59 (1995) 6-7
84. Schaedel O., and Reiter Y. Antibodies and their fragments as anti-cancer agents. Curr Pharm Des 12 (2006) 363-378
85. Clarke M.F., Dick J.E., Dirks P.B., et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66 (2006) 9339-9344
86. Dirks P.B. Brain tumor stem cells. Biol Blood Marrow Transplant 11 (2005) 12-13
87. Dirks P.B. Cancer: stem cells and brain tumours. Nature 444 (2006) 687-688
88. Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64 (2004) 7011-7021
89. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 63 (2003) 5821-5828
90. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
91. Larson R.A., and Le Beau M.M. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact 153-154 (2005) 187-195